

Date: April 03, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, it is hereby informed that, the wholly owned subsidiary of the Company, i.e. Senores Pharmaceuticals, Inc., USA (“**SPI**”), has entered into an Operating Agreement dated April 02, 2026 (“**Agreement**”) to form a Joint Venture company named **Amerisyn, LLC** (“**Amerisyn**”) in the state of North Carolina, USA. As per the terms of the Agreement SPI has subscribed to 70% of the membership interest in Amerisyn, which accordingly, has become a step-down subsidiary of the Company.

The details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as **Annexure-A**.

This is for your information and records. The same is also being uploaded on the website of the Company at www.senorespharma.com.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Disclosure under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Name: Amerisyn, LLC Turnover: Not applicable as it is a newly formed entity.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not applicable, as this intimation is regarding the formation of a step-down subsidiary of the Company.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Pursuant to the Operating Agreement (" Agreement ") dated April 02, 2026, the wholly owned subsidiary of the Company i.e., Senores Pharmaceuticals, Inc. ("SPI"), has subscribed to 70% membership interest in Amerisyn, LLC, which, accordingly, has become a step-down subsidiary of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Not applicable
8.	Cost of acquisition or the price at which the shares are acquired	Not applicable
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	70% of the total membership interest of the step-down subsidiary i.e., Amerisyn, LLC, has been subscribed by the wholly owned subsidiary of the Company i.e., Senores Pharmaceuticals, Inc. with effect from April 02, 2026.

Senores Pharmaceuticals Limited


1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Sr. No.	Particulars	Description
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of formation of Amerisyn, LLC: March 05, 2026 Date of subscription to membership interest: April 02, 2026 3 Year Turnover: Not applicable Country of presence: United States of America

Committed to
Global Wellness!



Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263